Sodium–glucose co‐transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism

Over the last three decades, several lifesaving therapies for the treatment of heart failure with reduced ejection fraction (HFrEF) have emerged; however, this is not the case for heart failure with preserved ejection fraction (HFpEF). Sodium–glucose co-transporter 2 (SGLT2) inhibitors have emerged as a novel foundational therapy in patients with HFrEF.1, 2 Initially developed as a treatment for diabetes, accumulating evidence from the DAPA-HF...